Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of brostallicin in platinum-resistant or platinum-refractory ovarian cancer
2005-005646-39Phase 2Completed
- Sponsor
- Nerviano Medical Sciences
- Start
- Mar 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brostallicin in ovarian cancer, sponsored by Nerviano Medical Sciences. Primary endpoint: Objective tumor response rate. Started Mar 2006; status: completed.
02
Drugs
brostallicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2005-005646-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005646-39.